Orphazyme: Anticipated product approval to secure transformational year
Orphazyme predicts lower operating result in transformational 2021.
BY RITZAU FINANS, TRANSLATED BY NIELSINE NIELSEN
Danish biotechnology firm Orphazyme, which develops medication for rare diseases, forecasts an operating deficit at DKK 100m-150m (USD 16.2m-24.2m) in 2021, which is significantly lower than the realized deficit for 2020 at DKK 608m, according to the firm's 2020 annual report.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Orphazyme recruits new CEO
For subscribers
